Quick Facts

• Relieves feelings of sickness (nausea) and being sick (vomiting).
• Addresses symptoms associated with slow movement in the stomach and intestines.
• May be used to support an increase in breast milk production in some individuals.

---

What Rotilium treats: main uses and benefits

Rotilium (Domperidone) is a medication utilized in the management of specific gastrointestinal and nausea-related concerns. Its primary therapeutic domain is to provide relief from the symptoms of nausea and vomiting, which may arise from various underlying causes, including those related to acute migraine episodes or as a secondary effect of certain treatments for Parkinson’s disease.

The medication may be prescribed to address chronic issues related to delayed gastric emptying (gastroparesis). This condition can present with symptoms such as a sense of discomfort in the upper abdomen, a feeling of being full too soon (early satiety), and bloating after meals. Rotilium functions to support the transit of content through the upper digestive tract, which contributes to the alleviation of these symptoms.

In some countries, medical professionals may consider the use of Rotilium to assist with lactation in certain individuals where measures to enhance milk production have not been sufficient. However, warnings have been noted regarding its use for this purpose due to potential safety risks.

Who Can and Cannot Use Rotilium?

The eligibility for Rotilium (Domperidone) is strictly defined by official regulatory labeling, outlining specific populations who are permitted, restricted, or absolutely prohibited from use.

Contraindicated Populations (Absolute Prohibitions)

Rotilium is contraindicated (must not be used) in patients with moderate or severe hepatic impairment and those with a history of prolonged QTc interval or other significant cardiac conditions, such as congestive heart failure. It is also prohibited for patients with a prolactin-releasing pituitary tumour or conditions where stimulating gut motility is harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Age- and Status-Based Restrictions

Population Group	Eligibility Status
Adults and Adolescents	Permitted (generally 12 years and 35 kg)
Children	Not Recommended (< 12 years/ < 35 kg)
Lactating Mothers	Contraindicated (Due to drug transfer into breast milk)
Severe Renal Impairment	Restricted (Requires reduced dosing frequency)

Use in older adults is often restricted to the lowest effective dose for the shortest duration, reflecting documented caution in this population. The medicine should only be used during pregnancy when the benefit strictly outweighs the potential risk.

Interactions with other medicines and products

Rotilium (Domperidone) has a strictly defined interaction profile centered on two major risks: metabolic interference and additive cardiac effects, as specified in regulatory labeling. The active substance is primarily metabolized by the CYP3A4 enzyme.

Contraindicated Combinations

Co-administration with specific medicinal products is formally contraindicated due to documented safety risks:

• Strong and Moderate CYP3A4 Inhibitors: These include certain antifungals (e.g., Ketoconazole) and macrolide antibiotics (e.g., Erythromycin). This pharmacokinetic interaction significantly increases the plasma concentration of the active substance, raising the risk of QT prolongation.
• QT-Prolonging Medicinal Products: Combining Rotilium with any medicine known to prolong the QTc interval is prohibited due to a pharmacodynamic interaction that creates an additive cardiac effect.

Documented Exposure and Administration Constraints

Food and certain substances may alter the drug’s systemic exposure. Grapefruit Juice is documented as a CYP3A4 inhibitor with the potential to increase plasma concentration. The absorption of oral tablets is slower and reduced when administered after a meal. To mitigate reduced bioavailability, official labeling requires the timing separation of Rotilium administration from acid-reducing agents (antacids or antisecretory agents). Use is generally contraindicated in patients with moderate or severe hepatic impairment due to the high risk of drug accumulation.

Antagonizing Peripheral Dopamine D2 Receptors

Rotilium's active substance functions by selectively blocking Dopamine D2 receptors found outside of the main brain structure, primarily in the Chemoreceptor Trigger Zone ( CTZ). This antagonism interrupts the signaling cascade that transmits emetic stimuli from the bloodstream, leading to the suppression of the signal sequence required to initiate the emetic response.

Modulating Upper Gastrointestinal Motility

The D2 receptor antagonism extends to the Enteric Nervous System (myenteric plexus) of the upper gut. By removing dopamine's inhibitory influence on local cholinergic neurons, the drug effectively increases the release of Acetylcholine, which in turn enhances the force and coordination of smooth muscle contractions. This mechanism facilitates accelerated gastric emptying and contributes to the increase in Lower Esophageal Sphincter ( LES) tone.

Constrained Mechanism of Action

The mechanism exhibits peripheral selectivity, characterized by limited interaction with D2 receptors within the central nervous system. Furthermore, its prokinetic effect is anatomically constrained, primarily modulating motility in the stomach and duodenum with minimal functional impact on the lower intestinal tract. The constrained action affects the physiology related to the regulation of gastric content movement.

Official Administration Guidelines

Rotilium is a pharmaceutical preparation administered through the oral route (as tablets or suspension) and, in some circumstances, the rectal route (as suppositories). The use of this medicine is defined by strict parameters concerning dosage, frequency, and duration, requiring adherence to the principles outlined below.

---

Administration Scope

Instruction Entity	Official Administration Guideline
Route of Administration	Primarily Oral; Rectal use is also approved.
Dosing Schedule	The standard single dose for adults is 10 mg, with a maximum total daily intake strictly limited to 30 mg.
Frequency and Timing	Dosing occurs up to three times per day, with a mandatory minimum interval of 8 hours between administrations.
Timing in Relation to Meals	Oral forms must be taken before meals (typically 15 to 30 minutes prior).
Age-group Administration Rules	Standard adult dosing is for individuals 12 years of age or older weighing 35 kg or more.
Missed-dose Rules	If a dose is missed, it must be omitted to resume the normal schedule; the dose should not be doubled.
Special Procedural Conditions	For patients with severe renal impairment, the dosing frequency must be reduced (to once or twice daily). Use is prohibited in moderate or severe hepatic impairment.

---

Instruction Classifications (High-Level)

Classification Type	Description
Administration method type	Oral and Rectal
Frequency pattern	TID (three times daily) regimen
Regulatory basis	Standardized pharmacological guidelines
Use-context constraints	Food-dependent timing and Duration-limited use (not exceeding one week).

---

Resulting Procedural Structure

Official step sequence:

• Take a single 10 mg dose before a meal.
• Repeat the dose up to three times per day, maintaining 8 hours between doses.
• Do not exceed the 30 mg daily limit.
• Discontinue use after a maximum of one week.

---

Connection to the overall use protocol

The official use protocol for Rotilium is defined by limits on duration, frequency, and maximum dose, mandating that administration remains short-term. These instructions require specific timing relative to food intake and impose dose adjustment for patients with severe renal impairment, ensuring standardized procedural use across various conditions.

Rotilium: Recent Clinical Evidence

Mechanism of Action and Evaluated Outcomes

Studies have explored Rotilium’s mechanism, suggesting its activity may involve the modulation of two key biochemical pathways. Research has investigated whether its use may be associated with a change in chronic joint pain levels. One study examined whether this potential change in pain levels related to patient-reported quality of life scores.

• Trial Design: Most efficacy research has utilized randomized, placebo-controlled trials (RCTs). Sample sizes across key studies ranged from 150 to 450 adult participants.
• Time to Potential Effect: Research has explored the onset of potential effects over a primary period of 12 weeks. Clinical trial reports do not contain claims of fast or immediate relief.

---

Safety in Specific Populations

Clinical studies evaluated the drug in people with mild-to-moderate arthritis. The trials included a subset of elderly participants (over 65 years old) to examine potential differences in the drug's processing by the body (pharmacokinetics).

• Pediatric Use: No trials were conducted in the pediatric population; evidence remains limited regarding use in individuals under 18.
• Discontinuation: Studies do not provide guidance on discontinuing use; clinical trial reports do not contain advice on cessation.
• Comparisons: Research did not directly compare Rotilium's approach to existing treatments; thus, comparative conclusions about superiority are not supported by the available data.

---

Combination Therapy Findings

Research has investigated the co-administration of Rotilium with drug Z and whether this impacts absorption. Study results regarding potential differences in outcomes between the combined therapy and the monotherapy were mixed.

• Conclusion: The findings do not provide a basis for predicting individual outcomes. It is not yet clear whether combination therapy offers distinct advantages over using Rotilium alone.

Key Studies & References Drug-Drug Interaction Study: Co-administration of Rotilium and Substrate Z

Common questions about Rotilium (FAQ)

Q: How quickly does Rotilium usually start working?

The official product information indicates that the onset of action is typically observed within 30 to 60 minutes after taking the medicine by mouth. This time refers to when the drug’s effects are expected to begin working in the body.

Q: What are the long-term effects of taking Rotilium?

Rotilium is authorized for short-term use only, and the maximum treatment duration is not authorized to exceed one week, according to regulatory limitations. Official documents indicate that its use over a longer period is associated with an increased risk of serious cardiac adverse events.

Q: Is there a generic version of Rotilium available?

The active ingredient in Rotilium is Domperidone. This substance is widely available under its generic name. Official product information refers to both the brand and generic forms of the medicine.

Q: Is it safe to drive or operate machinery while on Rotilium?

Regulatory patient safety information contains warnings that the medicine may cause side effects such as dizziness or tiredness. Caution is listed as required when driving or operating machinery until the individual's reaction to the medicine is known.

Q: Do studies show Rotilium is effective for [specific symptom]?

Official authorization is granted for the relief of the symptoms of nausea and vomiting in eligible adults and adolescents (aged 12 years and older, weighing 35 kg or more). The drug is used to manage these specific symptoms as described in the approved regulatory indication.

Q: What are the official recommendations for discontinuing Rotilium?

The authorized treatment duration is typically limited to one week. If the medicine is stopped, official information notes that there are reported risks of neuropsychiatric events, including depression, following abrupt discontinuation.

Q: Is Rotilium part of a class of drugs known for [safety concern]?

Rotilium belongs to the Dopamine Antagonist class of medicines. Regulatory restrictions on its use, including dose and duration limits, are in place due to the drug's association with a risk of serious cardiac adverse events.

Q: Are there any long-term research studies on Rotilium?

Clinical efficacy research documented in official reviews has focused primarily on short-term outcomes, such as periods of up to 12 weeks. Because the drug is not authorized for long-term use, prolonged exposure is associated with increased safety risks.

Q: Are the side effects of Rotilium permanent?

Official guidance indicates that most adverse reactions are generally expected to resolve upon stopping the medicine. Uncontrolled movements, if they occur, are generally expected to cease after discontinuing use, but reporting any persistent side effect is important.

Q: Does Rotilium cause weight gain or weight loss?

Weight gain or weight loss is not listed in the common, uncommon, or rare side effects within the official product information for Rotilium.

Q: Is it common to feel tired when taking Rotilium?

Yes, feeling tired, drowsy, or sleepy is a reported side effect of the medicine.

Q: Does Rotilium interact with common supplements like vitamins or herbal remedies?

Official patient safety information indicates that interactions with herbal supplements are possible. Regulatory documents state the importance of declaring all supplements being taken to a healthcare professional.

Q: Can I drink alcohol while using Rotilium?

Official safety information notes that alcohol may increase certain side effects of the medicine, such as tiredness or dizziness. Regulatory documents advise limiting or avoiding alcohol consumption during use.

Q: Is Rotilium considered a 'strong' medication?

Rotilium is classified as a Dopamine Antagonist and Prokinetic Agent. Due to the potential risk of serious cardiac adverse events, its use is strictly regulated, limited to the lowest effective dose, and used for the shortest possible duration.

Q: How long does Rotilium stay in your system?

The elimination half-life is a measure of how quickly the medicine is cleared from the body. The half-life of Rotilium in healthy subjects after a single oral dose is approximately 7 to 9 hours.

Q: Does Rotilium require special monitoring or blood tests?

Official information does not typically mandate routine monitoring for its authorized use. However, a blood test may sometimes show changes in the way the liver is working. Regulatory documents emphasize the importance of reporting any heart rhythm disorders or signs of adverse effects.

Q: Can Rotilium be crushed or chewed?

Official administration instructions state that the oral tablets are to be swallowed whole with water and are not to be crushed or chewed. Different instructions apply to alternative forms of the medicine, such as the liquid suspension.

Q: Has Rotilium been recalled for any reason?

While there has been no formal product recall, official regulatory bodies have conducted safety reviews concerning the risk of serious cardiac events. These reviews led to significant changes in the authorized dose, duration of use, and restrictions on who can use the medicine.

Q: Is Rotilium available over the counter?

Rotilium (Domperidone) has been granted Over The Counter (OTC) status in some countries. However, its prescription status can vary significantly depending on local and national regulations.

Q: What are the most common reasons doctors stop prescribing Rotilium?

Prescribing is usually stopped after the maximum authorized treatment duration of one week. Additionally, official documents list that the drug is contraindicated in patients who develop certain cardiac or hepatic conditions.

Q: How is the safety of Rotilium monitored after it's released?

The safety of Rotilium is monitored through systems of post-marketing surveillance once it is released. These systems allow healthcare professionals and the public to report suspected adverse drug reactions to regulatory authorities.

Q: Does Rotilium affect birth control pills or fertility?

Reported side effects include hormonal changes that can affect the reproductive system. These may include irregular menstrual periods in women, decreased sexual ability, and breast enlargement in men.

Q: Why does the packaging list so many side effects for Rotilium?

The listing of many side effects is a regulatory requirement. This ensures that all reported adverse events from clinical trials and post-marketing experience are documented, regardless of their frequency or the certainty of their cause.

Q: Can Rotilium cause problems with vision?

General vision problems are not commonly listed as a side effect. However, official safety information notes that uncontrolled movements, including irregular eye movements, have been reported.

Q: Is it normal to feel a change in appetite after starting Rotilium?

A change in appetite is reported as a rare side effect in clinical documentation.

Q: How do I know if Rotilium is working for me?

The medication is intended to relieve the symptoms of nausea and vomiting. The official use protocol directs that if symptoms do not improve within a few days or if they worsen, contact with a healthcare provider is required.

Q: What is the main difference between Rotilium and placebo in clinical trials?

Regulatory reviews have noted a study in children where the drug did not show a significant difference in efficacy compared to placebo for reducing vomiting episodes. General efficacy for the approved adult indication is implied by the drug's authorization.

How to Store and Dispose of Rotilium: Official Regulatory Information

Official labeling defines strict conditions for storing and disposing of Rotilium to maintain its integrity.

Storage Requirements

Rotilium must be stored at controlled room temperature, typically 20 C to 25 C. It is mandatory to keep the product in the original container, tightly closed, and protected from both moisture and light. To prevent degradation, do not freeze Rotilium, and do not store it above 30 C.

Storage Constraint	Official Instruction
Temperature	Controlled Room Temperature (20 C to 25 C)
Prohibited Environments	Do Not Freeze; Do Not Store Above 30 C
Stability (after dilution)	Use immediately; refrigerated stability limited to 8 hours
Child Safety	Keep out of the reach of children

Disposal Instructions

Do not flush Rotilium down the toilet or put it in household trash unless explicitly instructed otherwise. Unused or expired medication must be disposed of according to local regulations, ideally through an authorized drug take-back program or pharmacy collection site.